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Abstract 
Aims: Peritonitis is one of the most common causes of sepsis, a serious syndrome characterized by a 
dysregulated systemic inflammatory response. Recent evidence suggests that Granzyme A (GzmA), a 
serine protease mainly expressed by NK and T cells, could act as a proinflammatory mediator and could 
play an important role in the pathogenesis of sepsis. This work aims to analyze the role and the 
therapeutic potential of GzmA in the pathogenesis of peritoneal sepsis.  
Methods: The level of extracellular GzmA as well as GzmA activity were analyzed in serum from healthy 
volunteers and patients with confirmed peritonitis and were correlated with the Sequential Organ Failure 
Assessment (SOFA) score. Peritonitis was induced in C57Bl/6 (WT) and GzmA-/- mice by cecal ligation 
and puncture (CLP). Mice were treated intraperitoneally with antibiotics alone or in combination 
serpinb6b, a specific GzmA inhibitor, for 5 days. Mouse survival was monitored during 14 days, levels of 
some proinflammatory cytokines were measured in serum and bacterial load and diversity was analyzed 
in blood and spleen at different times. 
Results: Clinically, elevated GzmA was observed in serum from patients with abdominal sepsis 
suggesting that GzmA plays an important role in this pathology. In the CLP model GzmA deficient mice, 
or WT mice treated with an extracellular GzmA inhibitor, showed increased survival, which correlated 
with a reduction in proinflammatory markers in both serum and peritoneal lavage fluid. GzmA deficiency 
did not influence bacterial load in blood and spleen and GzmA did not affect bacterial replication in 
macrophages in vitro, indicating that GzmA has no role in bacterial control. Analysis of GzmA in lymphoid 
cells following CLP showed that it was mainly expressed by NK cells. Mechanistically, we found that 
extracellular active GzmA acts as a proinflammatory mediator in macrophages by inducing the 
TLR4-dependent expression of IL-6 and TNFα.  
Conclusions: Our findings implicate GzmA as a key regulator of the inflammatory response during 
abdominal sepsis and provide solid evidences about its therapeutic potential for the treatment of this 
severe pathology. 










Peritonitis is an inflammation of the peritoneum, 
usually following infection of the serous membrane 
that covers the abdominal cavity and the organs 
contained therein [1]. Peritonitis is classified as 
primary, secondary or tertiary depending on disease 
severity and effect on the different organs [2]. Primary 
peritonitis is associated with undamaged intra- 
abdominal cavity organs. The most frequent forms are 
spontaneous bacterial peritonitis, associated with 
advanced liver disease (infected ascites), and infection 
in patients undergoing peritoneal dialysis. Secondary 
peritonitis is an infection in the peritoneal cavity due 
to a perforation of the gastrointestinal tract by 
ulceration, ischemia or obstruction; a post-surgical 
infection or a closed or penetrating trauma. Tertiary 
peritonitis is a persistent intra-abdominal infection 
after at least 48 hours of adequate therapy of primary 
or secondary peritonitis [2]. Peritonitis is a leading 
cause of sepsis [1], a serious syndrome characterized 
by a dysregulated systemic inflammatory response [3, 
4]. 
Granzymes (Gzms) are a family of serine 
proteases that, together with perforin, constitute the 
main components of the cytotoxic lymphocyte 
granule exocytosis pathway. Gzms are classified 
according to their cleavage specificity. Five Gzms in 
humans (A, B, H, K, and M) and ten in mice (A, B, C, 
D, E, F, G, K, M and N) have been described [5]. The 
granule exocytosis pathway is a specialized form of 
intracellular protein delivery by which lymphocytes 
release perforin and Gzms into infected or 
compromised cells. Perforin creates short-lived pores 
in the plasma membrane of target cells allowing the 
passage of Gzms into the cytosol of target cells where 
they carry out their effector functions [6]. Gzms can 
also be released into the extracellular milieu where 
they regulate different extracellular processes 
independently of their ability to induce cell death [5, 
7]. Traditionally, it was assumed that all Gzms acted 
as cytotoxic proteases. However, recent evidence 
suggests that only GzmB has clear cytotoxic capacity, 
while the cytotoxicity of others such as GzmA and 
GzmK is controversial [6, 8-12]. 
It has been recognised that some Gzms like 
GzmA may act as pro-inflammatory mediators 
contributing to the pathophysiology of different 
inflammatory disorders including rheumatoid and 
viral arthritis [13, 14], colitis [15], endotoxicosis [16, 
17] or bacterial sepsis [18, 19]. Furthermore, in vitro 
studies have reported that GzmA induces the 
expression of pro-inflammatory cytokines in several 
cell types including monocytes, macrophages, 
endothelial and epithelial cells and fibroblasts [16, 
20-23]. However, the role of GzmA in abdominal 
sepsis, the second most common form of sepsis in 
humans, is not known.  
This study aimed to analyse the involvement of 
GzmA in abdominal sepsis, and gain insight into its 
therapeutic potential. We examined serum samples 
from patients with intraabdominal sepsis; and 
investigated the role of GzmA in sepsis using the 
Cecum Ligation and Puncture (CLP) mouse model, 
which best mimics the septic response during human 
peritonitis [24].  
Results 
Extracellular GzmA is increased in patients 
undergoing abdominal sepsis 
We analysed the levels of GzmA in serum from 
patients with abdominal sepsis, who were diagnosed 
with peritonitis with a SOFA (Sepsis related Organ 
Failure Assessment) score >2, and compared with the 
levels in serum from healthy donors. Patient 
characteristics are included in Table 1. There were 6 
males and 4 females, the medium age was 76 years 
and 3 patients deceased after 30 days. Patients with 
peritoneal sepsis presented elevated levels of GzmA 
at time of diagnosis (time 0) and for 72 h thereafter 
that were significantly above healthy donor levels 
both diagnosis and after 24 h (Figure 1). This shows 
that serum GzmA is elevated during abdominal sepsis 
and suggests that extracellular GzmA could be 




Figure 1. Increased levels of extracellular GzmA are observed in patients 
with abdominal sepsis. Serum levels of GzmA were analysed by ELISA in healthy 
donors (n = 10) and compared with GzmA levels from patients with a diagnosis of 
abdominal sepsis (n = 10) at diagnosis (time 0 = disease onset) and during the first 72 
h. Statistical analyses were performed by one-way ANOVA test with Bonferroni’s 
post-test *P < 0.05; **P < 0.01. DL (ELISA Detection Limit). 





Table 1. Clinical data of abdominal sepsis patients. 
Patient SOFA score Gender Age Status at day 30 Co-morbidities 
1 2 Male 62 Alive Gastric tumor + chemotherapy 
2 2 Male 68 Alive Coronary disease, peripheral vascular disease, peptic ulcer  
3 5 Female 75 Dead Dementia, cerebrovascular disease, renal disease, diabetes with damage to target organs 
4 7 Female 72 Alive Congestive heart failure, connective tissue disease (immunosuppression), renal disease 
5 7 Male 75 Alive Diabetes, bile-duct tumor 
6 8 Male 67 Alive Coronary disease, congestive heart failure, diabetes with damage to target organs 
7 6 Female 78 Dead None 
8 6 Male 90 Alive None 
9 7 Female 82 Dead Cerebrovascular disease, peptic ulcer, renal disease, renal tumor 




Figure 2. The absence of granzyme A increases survival in mice during CLP and E. coli-induced sepsis. Sepsis was induced by CLP in WT and GZMA-/- mice (A) and 
GZMA-/- and GZMA+/+ littermates (B) as described in materials and methods. After 6 h, a mixture of antibiotics, ceftriaxone (30 mg/kg) + Metronidazole (12.5 mg/kg) was 
administered i.p. every 24 h for 5 days. WT and GZMA-/- sham operated mice underwent the same procedure but without the ligation and puncture of the cecum. Survival was 
monitored during 14 days. The data correspond to the indicated number of biological replicates (individual mice) from three independent experiments. Statistical analyse was 
performed using logrank and Gehan-Wilcoxon test. *p < 0.05. (C) WT and GZMA-/- mice were infected i.p. with 2 x 108 CFU of E. coli as described in materials and methods. The 
data corresponds to the indicated number of biological replicates from two independent experiments. Statistical analyse was performed using logrank and Gehan-Wilcoxon test. 
*p < 0.05. (D) An in vitro analysis was performed to determine the capacity of GzmA in the control of bacterial pathogens. M1 macrophages were differentiated as described in 
material and methods. Macrophages were incubated with GZMA (300 nM), infected with E. coli (MOI 1:100) and incubated for 4, 24 and 48 h at 37 °C. After incubation time cells 
were lysed and the number of CFU was determined. Data are presented as mean ± SEM from 3 independent experiments. 
 
GZMA deficient mice are protected from CLP 
Once we had observed increased levels of 
extracellular GzmA in patients with abdominal sepsis, 
we decided to analyse the relevance of these findings 
by testing the role of GzmA in the CLP mouse model, 
one of the murine models that better mimics the 
complex septic response in human abdominal sepsis 
[24]. A severe sepsis CLP protocol was applied to WT 
and GZMA-/- mice as indicated in methods. In order 
to mimic the clinical management of septic patients, a 
broad-spectrum antimicrobial treatment was 
administered starting six hours after CLP, and 
survival monitored for 14 days. 
As shown in Figure 2A survival of GZMA-/- mice 
was significantly higher than WT controls. Less than 
40% of WT mice survived CLP, while more than 70% 
of GZMA-/- mice were still alive after 2 weeks. As 
expected, all sham mice survived, which confirms that 
the surgical technique was performed effectively. 
When control littermates (Figure 2B) were used a 
similar result was found, confirming discarding that 
minimal differences in genetic background between 
WT and GZMA-/- mice could influence the results. 
These results indicate that GzmA plays an important 
role during severe abdominal sepsis induced by CLP 
in vivo. To confirm the role of GZMA in peritoneal 
sepsis we employed E. coli-induced sepsis as 





additional model. As shown in Figure 2C, GZMA-/- 
mice survived significantly longer than WT mice 
confirming the results obtained in CLP model. Finally, 
incubation of GzmA with macrophages infected with 
E. coli did not potentiate inhibition of bacterial 
replication (Figure 2D), indicating that the results 
obtained in vivo are not influenced by changes in 
bacterial replication in the absence of GZMA (see also 
Figure 4). 
GZMA deficient mice show reduced levels of 
proinflammatory cytokines during abdominal 
sepsis 
Next, we analysed if the protection observed in 
GZMA deficient mice during sepsis induced by CLP 
correlated with reduced serum level of 
proinflammatory cytokines. Thus, we monitored the 
concentrations of IL-6, IL-1α, IL-1β and TNFα in 
plasma and peritoneal lavage fluid (Figure 3). 
GZMA-/- mice showed significantly lower levels of all 
cytokines in both plasma and peritoneal lavage fluid 
after 6 and/or 24 h of CLP induction. It should be 
noted that although all cytokines were reduced in the 
biological fluids of GZMA-/- mice after CLP, only IL-6 
and IL-1α were significantly lower than controls at 6 h 
in both plasma and peritoneal fluid. After 24 h all 
cytokines, IL-6, IL-1α, IL-1β and TNFα, were 
significantly reduced in septic GZMA-/- mice. This 
confirms that GzmA regulates the generation of 
proinflammatory cytokines in vivo during abdominal 
sepsis. 
The absence of GzmA does not compromise 
anti-bacterial control during CLP 
GZMA deficiency reduces the generation of 
inflammatory cytokines in vivo. Thus, it is possible 
that the reduced inflammatory response affects 
efficient clearance of local and/or systemic bacterial 
infection after CLP. We analysed the total aerobic 
bacterial load in blood, spleen, liver, lungs and 
peritoneal fluid during CLP-induced sepsis. As 
shown in Figure 4A, WT and GZMA-/- mice exhibited 
similar bacterial loads in peritoneal lavage fluid, 
blood, liver, spleen and lung after 6 and 24 h of sepsis 
induction. Although total bacterial counts were 
similar in both mouse strains, it is possible that the 
control of specific bacterial species is compromised in 
the absence of GzmA. Thus, we characterised the 
bacterial species presented in the different organs and 
fluids and quantified their individual level by 
MALDI-TOF mass spectrometry. The analysis 
showed that the most frequent species present were 
Lactobacillus murinus, Enterococcus faecalis, 
Staphylococcus sciuri, Streptococcus sp and Escherichia 
coli. The bacterial load of these species in WT and 
GZMA-/- mice was similar in peritoneal fluids, blood, 
spleen, liver and lung, after 6 and 24 h of sepsis 
induction (Figure 4B). These results indicate that 
GzmA deficiency does not compromise control of 
aerobic bacteria during polymicrobial abdominal 
sepsis and together with figure 2D indicate that the 
effect of inflammatory effect of GzmA does not 
contribute to bacterial control. 
GzmA expression increases in NK cells during 
abdominal sepsis 
Once we confirmed that the absence of GzmA 
increases the survival of mice during abdominal 
CLP-induced sepsis, correlating with a reduced 
inflammatory response that did not compromise 
bacterial control, we decided to establish the cellular 
source of GzmA. We focused on the major cell 
populations known to express GzmA in blood and 
spleen [5]: NK and T cells, including NKT cells. The 
gating strategy is summarised in Figure 5A. Cells 
were stained with NK1.1, CD3, CD4 and CD8 
antibodies in order to distinguish NK cells 
(NK1.1+CD3- cells) from the main T cell subsets, NKT 
(NK1.1+CD3+), CD4+ T (NK1.1-CD3+CD4+) and CD8+T 
(NK1.1-CD3+CD8+) cells. As shown in Figure 5A, the 
relative presence of these populations was not 
different between WT and GZMA-/- mice confirming 
that the absence of GzmA does not influence these 
immune cell responses. GzmA expression was 
significantly enhanced in NK cells from septic mice in 
both spleen and peripheral blood. In contrast, the 
expression of GzmA in the main T cell subsets (NKT, 
CD8+ T or CD4+ T cells) was very low and did not 
increase during sepsis (Figure 5B).  
Therapeutic inhibition of GzmA with 
Serpinb6b increases survival and reduces 
inflammation during CLP 
Once the effect of GzmA absence was analysed 
using a genetically deficient model, we decided to 
further analyse the potential of using GzmA as 
therapeutic target to treat abdominal sepsis. To this 
aim we analysed the effect of a GzmA inhibitor on WT 
animals undergoing abdominal sepsis. We used 
serpinb6b, a recently described natural specific 
inhibitor of mouse GzmA, which does not inhibit 
other gzms [25]. After sepsis induction a group of WT 
and GZMA deficient mice were treated with the 
inhibitor and survival was monitored during 14 days. 
As shown in Figure 6A, WT mice treated with 
antibiotics and serpinb6b showed a significant 
improvement in survival compared with WT mice 
treated with antibiotics only. Survival of septic WT 
mice treated with serpinb6b was similar to the 
survival of GZMA deficient mice. In contrast, the 





inhibitor did not have any effect on GZMA deficient 
mice suggesting that the effect observed in WT mice 
was specifically a consequence of GzmA inhibition. In 
parallel, a group of mice treated or not with the 
inhibitor were sacrificed and the level of IL-6 in 
plasma and peritoneal fluid was determined. Since all 
cytokines were reduced in GZMA-/- mice after 24 h, 
we decided to focus only in IL-6 in WT mice treated 
with the inhibitor as a representative cytokine in order 
to confirm the results obtained in GZMA-/- mice. In 
WT mice the therapeutic inhibition of GzmA 
significantly reduced the level of IL-6 in plasma and in 
peritoneal fluids. By contrast, the administration of 
serpinb6b in septic GZMA-/- mice did not reduce the 
levels of IL-6, again confirming the specificity of 
serpinb6b to inhibit GzmA (Figure 6B). The ability of 
serpinb6b to inhibit the enzymatic activity of GzmA 
was also confirmed (Figure 7). These results confirm 
that GzmA inhibition in septic WT mice mimics the 
effect observed in GZMA deficient mice and provide a 
proof of principle that inhibition of GzmA could be 
useful for the treatment of abdominal sepsis. 
 
 
Figure 3. The absence of granzyme A reduces the level of proinflammatory cytokines during sepsis induced by CLP. Sepsis was induced by CLP in WT and 
GZMA-/- mice as described in materials and methods. After 6 h, a mixture of antibiotics, ceftriaxone (30 mg/kg) + metronidazole (12.5 mg/kg) was administered every 12 h. WT 
and GZMA-/- sham operated mice underwent the same procedure but without CLP. After 6 or 24 h of sepsis induction, mice were sacrificed and the levels of IL-1α, IL-1β, TNFα 
and IL-6 in plasma and peritoneal lavage fluids were determined by ELISA. Data are presented as mean ± SEM of 5 (sham) or at least 8 (CLP) different biological replicates 
(individual mice) from 3 independent experiments. Statistical analysis was performed by one-way ANOVA test with Bonferroni’s post-test *P < 0.05; **P < 0.01; ***P < 0.001. 






Figure 4. GzmA is not involved in the control of bacterial pathogens during sepsis induced by CLP. Sepsis was induced by CLP in WT and GZMA-/- mice as 
described in materials and methods. After 6 h, a mixture of antibiotics, ceftriaxone (30 mg/kg) + Metronidazole (12.5 mg/kg) was administered i.p. every 12 h. After 6 and 24 h 
of sepsis induction, a group of mice were sacrificed and the total number of CFU from aerobic bacteria was determined in peritoneal fluids, blood, spleen liver and lung (A). The 
most frequent strains were identified by MALDI-TOF mass spectrometry and the number of CFU of these strains was determined in peritoneal lavage fluids, blood, spleen liver 
and lung (B). Data are presented as mean ± SEM from 5 biological replicates (individual mice) in each group. 






Figure 5. GzmA expression is increased in NK cells from septic mice. Sepsis was induced by CLP in WT and GZMA-/- mice as described in materials and methods. Sham 
WT operated mice underwent the same procedure but without the ligation and puncture of the cecum. After 24 h mice were sacrificed and (A) the percentage of NK cells 
(NK1.1+CD3-), NKT cells (NK1.1+ CD3+), CD8+ T cells (CD8+ CD3+) and CD4+ T cells (CD4+, CD3+) and (B) the intracellular expression of GzmA on NK cells, NKT cells, 
CD8+ T cells and CD4+ T cells were analysed in splenocytes and PBLs by flow cytometry. A representative experiment of GzmA expression in spleen is shown via dot plot (A). 
Numbers show the cell percentage in each quadrant. Data in graphs represent the mean ± SEM of the percentage of GzmA positive cells of each phenotype (right) and the 
percentage of each subtype (left) from 2 independent experiments. (B) Statistical analysis was performed by unpaired student’s t test. **p < 0.01, ***p < 0.001. 






Figure 6. Inhibition of extracellular GzmA improves sepsis outcome and 
reduces inflammation. Sepsis was induced by CLP in B6 and GZMA-/- mice as 
described in materials and methods. Immediately after surgery mice were treated 
with 40 µg of Serpinb6b in 100 µl of PBS (10 WT and 9 GZMA-/- mice). This treatment 
was repeated 6 h later and once a day during 5 days. Control mice received only 100 
µl of PBS i.p. (13 WT and 6 GZMA-/- mice). After 6 h a mixture of antibiotics, 
ceftriaxone (30 mg/kg) + metronidazole (12.5 mg/kg) was administered i.p. once a day 
for 5 days. WT sham operated mice (4 WT mice) underwent the same procedure but 
without the ligation and puncture of the cecum. (A) Survival was monitored during 14 
days. The data correspond to the indicated number of mice combined from two 
independent experiments. Statistical analyse was performed using logrank and 
Gehan-Wilcoxon test. *p < 0.05. (B) 24 h after sepsis induction mice were sacrificed 
and the levels of IL-6 in plasma and peritoneal fluids was determined by ELISA. Data 
are presented as mean ± SEM of 4 (Sham) or 6 (CLP) biological replicates from 2 
independent experiments. Statistical analysis was performed by one-way ANOVA 
test with Bonferroni’s post-test *P < 0.05; **P < 0.01; ***P < 0.001. 
 
The inflammatory response induced by GzmA 
on mouse macrophages depends on TLR4 
expression 
Increased levels of GzmA were found in patients 
with abdominal sepsis (Figure 1) and human GzmA is 
known to induce the generation of inflammatory 
cytokines in monocytes and macrophages [16, 26]. 
Thus, in order to find out how extracellular GzmA 
contributes to abdominal sepsis, we analysed the 
generation of inflammatory cytokines in mouse 
macrophages in vitro. As shown in Figure 7A, mouse 
active GzmA significantly induced IL-6 expression in 
mouse macrophages. Inactive proGzmA or GzmA 
inhibited by Serpinb6b did not induce IL-6. As 
additional control we used cathepsin C the protease 
used to activate GzmA in the purification process. As 
expected, since cathepsin C is not active at pH higher 
than 6, this protease did not induce IL-6 production. 
The amount of LPS in the recombinant protein 
preparation was lower than 0.5 EU/µg. In addition, 
the GzmA inhibitor sepinb6b that completely blocked 
mouse GzmA activity (Figure 7B), abrogated the 
expression of IL6 in macrophages incubated with 
GzmA (Figure 7A), confirming that potential 
contaminants in GzmA preparations like cathepsin C 
or traces of LPS were not responsible of the 
inflammatory effect of extracellular GzmA. 
Next we analysed the potential involvement of 
TLR4 in this process. TLR4 is a key receptor activated 
by microbial PAMPs like LPS and different 
endogenous ligands or DAMPs [27] and it has been 
previously found to be involved in abdominal sepsis 
[28]. 
Thus, the effect of extracellular GzmA on the 
generation of IL-6 and TNFα by M1 bone 
marrow-derived macrophages from WT and TLR4 
deficient mice was analysed. We found that 
recombinant mGzmA produced in E. coli or in P. 
pastoris induced the expression of IL-6 and TNFα on 
M1 WT macrophages which was reduced in absence 
of TLR4 (Figure 7C). This result indicates that GzmA 
induces the expression of IL-6 by a mechanism 
dependent on TLR4.  
It has been reported that inactive human GzmA 
potentiates the proinflammatory effects of LPS in 
monocytes by a TLR4-dependent mechanism [26]. 
However, our results employing the GzmA inhibitor 
serpinb6b suggest that in our system the generation of 
proinflammatory cytokines is dependent on the 
enzymatic activity of mouse GzmA. Thus, we decided 
to analyse if mouse active GzmA potentiated the 
effect of LPS on mouse macrophages and the 
requirement of enzymatic activity for this potential 
effect. We employed a non-saturating low 
concentration of LPS (1 ng/mL) and three different 
concentrations of mGzmA. As shown in figure 7D 
GzmA inactivated with serpinb6b or inactive 
proGzmA did not induce IL-6 in macrophages. In 
addition, the combination of active GzmA, inactive 
proGzmA or GzmA inactivated with serpinb6b with 
LPS did not increase the level of IL-6 induced by LPS. 
Extracellular GzmA-mediated IL-6 induction 
in human monocytes is inhibited by 
antithrombin III 
Finally, we analysed if the results found in vitro 
in the mouse model were reproduced in human cells. 
As shown in Figure 7E, extracellular human GzmA 
induced IL-6 production in human monocytes, which 
was completely inhibited by the GzmA inhibitor 
antithrombin III (ATIII; serpinC1) in the presence of 
Heparin. Heparin or ATIII alone were not able to 
inhibit GzmA-mediated IL-6 production. As shown in 
Figure F we further confirmed that the presence of 
Heparin was required for ATIII-mediated inhibition 
of GzmA enzyme activity [29-31].  






Figure 7. Active extracellular GzmA induces the expression of IL-6 and TNFα in macrophages by a mechanism dependent of TLR4. (A) WT bone marrow 
differentiated macrophages were stimulated with LPS 100 ng/mL, active and inactive GzmA produced in E. coli, GzmA inactivated with sepinb6b and cathepsin C. After 24 h of 
incubation, supernatant was collected to determine the levels of IL-6 by ELISA. (B) GzmA activity was confirmed by an activity essay incubating active and inactive GzmA 
produced in E. coli, GzmA inactivated with sepinb6b and cathepsin C with a specific mouse GzmA substrate. Optical density at 405 nm was measured after 4, 12 and 24 h. (C) 
Macrophages differentiated from WT or TLR4-/- mouse bone marrow were stimulated with active GzmA (300 nM) produced in E. coli or in P. pastoris, GzmA inactivated with 
serpinb6b, LPS 100 ng/mL or S. aureus HK (1 x106 CFU/mL). After 24 h of incubation, the supernatant was collected to determine the levels of IL-6 and TNFα by ELISA. Data are 
represented as the mean ± SEM of two independent experiments performed by duplicate. Statistical analyses were performed by one-way ANOVA test with Bonferroni’s 
post-test, *P < 0.05, **P < 0.01; ***P < 0.001. (D) Macrophages were stimulated with LPS 1 ng/mL, GzmA (150 nM, 75 nM and 37,5 nM), inactive GzmA and serpinb6b. After 24 
h incubation, supernatants were collected to determine the levels of IL-6 by ELISA. (E) Human monocytes were obtained as described in materials and methods. 5 x 103 human 
monocytes were stimulated with LPS 100 ng/mL, human active GzmA and human GzmA inactivated with antithrombin III (ATIII) and heparin (HP). After 24 h incubation, 
supernatant was collected to determine levels of IL-6 by ELISA. Statistical analysis was performed by unpaired student’s t test, ***P < 0.001. (F) Human GzmA activity was 
confirmed by an activity essay incubating active human GzmA (300 nM), human GzmA inactivated with antithrombin III (ATIII) and heparin (HP) with a specific human GzmA 
substrate. Optical density at 405 nm was measured after 4, 12 and 24 h. 
 
Discussion 
In this study we have analysed the contribution 
of GzmA to abdominal sepsis by investigating the 
presence of extracellular GzmA in serum from 
patients with peritoneal sepsis as well as the role of 
GzmA in the mouse model of CLP. GzmA was found 
to be elevated in human serum from septic patients. 
The relevance of these findings was supported by the 
observation that GzmA deficient mice were resistant 
to CLP as well as to E. coli-induced sepsis. GzmA 





deficiency reduced inflammation without altering 
bacterial dissemination in the CLP model. A GzmA 
inhibitor enhanced survival and reduced 
inflammation in septic WT mice to a similar degree as 
observed with genetic deficiency, suggesting 
therapeutic potential in targeting GzmA in peritoneal 
sepsis.  
One of the advantages of CLP model is that the 
pathogens are endogenous, mimicking the traumatic 
injury that leads to peritonitis in humans. In addition, 
CLP sepsis shows a high degree of similarity with the 
progression of human sepsis, displaying both the 
hyper- and hypo-inflammatory responses 
characteristic of human sepsis [32, 33]. It has been 
shown previously that GzmA might contribute to 
septic shock induced by LPS [16, 17] or to sepsis 
induced by single bacterial agents like the mouse 
pathogen B. microti [18], S. pneumoniae [19] or E. coli 
[34]. However, the role of GzmA in abdominal 
polymicrobial sepsis had so far not been explored. 
Most importantly, the effect of GzmA inhibition in 
septic mice had not been analysed in any of these 
models. Our study thus adds to previous literature 
and confirms that GzmA is a key mediator of sepsis 
associated with different bacterial pathogens.  
Our data also suggest that inflammation induced 
by GzmA plays a critical role in the development of 
sepsis during peritonitis. We observed lower 
production of IL-1α, IL-1β, IL-6 and TNFα in serum 
and in peritoneal fluids in GzmA deficient mice. All 
these cytokines play an important role in sepsis 
[35-38]. In addition, our results employing an 
inhibitor of extracellular GzmA, serpinb6b, in vitro 
and in vivo, strongly suggest that GzmA enhances the 
inflammatory pathological response in sepsis in the 
extracellular space. Thus, since serpinb6b should not 
affect intracellularly perforin-delivered GzmA, we 
suggest that GzmA does not contribute to sepsis by 
promoting pyroptosis [39] or other types of cell death 
[40]. This suggestion is further supported by our 
results showing increased levels of extracellular 
GzmA in serum from patients with abdominal sepsis. 
Similar findings have been reported in other septic 
patients with human bacteraemia, tuberculosis and 
typhoid fever where high serum levels of GzmA have 
been detected [41-43] suggesting that this protease 
may have extracellular effects during other infectious 
diseases. But how does this protease regulate 
inflammation from the extracellular milieu? 
An important aspect to answer this question is 
the cell source of GzmA during sepsis. Here we have 
found that GzmA expression is increased in NK cells 
during CLP, supporting previous results in other 
models of sepsis [18, 34]. However, this finding does 
not exclude that GzmA expressed by other cell 
sources like platelets [23] or other cells [5] could 
contribute to polymicrobial abdominal sepsis.  
We describe here that active GzmA induces the 
expression of TNFα and IL-6 by a mechanism 
dependent of both its catalytic activity and TLR4. 
Supporting our findings in mouse macrophages, a 
recent study has found that human platelets acquire 
GzmA expression during aging and induce 
inflammation in human monocytes, a process 
inhibited by a TLR4 antagonist [23]. Confirming this 
finding, we have also shown that GzmA induces IL-6 
generation in human monocytes, which, similarly to 
mouse GzmA, was inhibited by SerpinC1/ATIII. 
Thus, it seems that both mouse and human 
extracellular GzmA regulates inflammation in 
monocytes and macrophages by a TLR4 dependent 
mechanism. However, it is not known yet if GzmA 
directly activates this receptor or could act on some 
other substrates that then act as ligands for TLR4. For 
example, GzmA can cleave fibronectin [44], and 
fibronectin fragments can activate TLR4 and induce 
inflammation [45]. Since extracellular GzmA induces 
the generation of IL-6 and TNFα in macrophages in 
the absence of cell death [46], it is unlikely that TLR4 
is activated by the release of inflammatory mediators 
as a consequence of GzmA-mediated cell death. In 
addition, several lines of experimental evidence 
indicate that TLR4 is not activated by contaminants 
present in the protease preparations. Inactivated 
GzmA was not able to induce inflammatory cytokines 
in mouse macrophages or human monocytes, and 
inflammation was similarly triggered by GzmA 
generated in E. coli or in P. pastoris both of which were 
not contaminated with LPS. In addition, it has also 
been shown by others that GzmA generated in human 
cells induces inflammation via a TLR4-dependent 
mechanism [23].  
Under normal conditions protease activity in 
blood is tightly regulated by extracellular inhibitors. 
Two circulating extracellular inhibitors are known for 
GzmA, antithrombin III (serpinC1) and 
α2-macroglobulin [47], suggesting that the protease 
activity can be regulated at the extracellular level. 
Interestingly, antithrombin III levels are markedly 
reduced in sepsis due to the reduction in liver 
synthesis, the consumption of this protein by the 
formation of thrombin-antithrombin complexes and 
by its degradation mediated by neutrophil-released 
elastase [48]. In addition, it has also been observed 
that in patients with sepsis the levels of 
α2-macroglobulin are decreased [49]. Therefore, 
supporting our findings it is possible that in sepsis, as 
natural GzmA inhibitors decrease, the active fractions 
of this protease in the bloodstream increase, 
explaining why extracellular GzmA remains active 





during sepsis. It has been reported that human GzmA 
potentiates LPS induced cytokine responses in human 
monocytes, an effect independent of the catalytic 
activity of GzmA [26]. In our study employing mouse 
GzmA in mouse macrophages and human GzmA in 
human monocytes, we have found that enzyme 
activity is required for the induction of IL6 and TNFα. 
In addition, in our system, active or inactive GzmA 
did not potentiate the effect of LPS. Other studies 
employing inhibitors or enzymatically inactive 
mutants have also found that enzyme activity is 
required for the inflammatory action of mouse and 
human GzmA [16, 50]. While the reasons for these 
apparently contradictory results are not known, it 
cannot be ruled out that both active and inactive 
forms of GzmA act as proinflammatory mediators in 
the plasma of septic patients. 
In conclusion, using GzmA deficient mice and 
direct inactivation of GzmA, we have demonstrated 
that extracellular GzmA plays an important role in 
sepsis pathogenesis. Other anti-inflammatory 
treatments including cytokine or TLR4 inhibitors have 
failed to improve sepsis survival in clinical trials [51, 
52]. However, a common limitation of those 
treatments is their potential impact on microbial 
control and, in addition, they could enhance the 
hypoinflammatory immunosuppressive stage. Thus, 
the beneficial effect of reducing inflammation might 
be counteracted by increasing the persistence of the 
pathogen(s) responsible for sepsis and/or by 
enhancing the susceptibility to second infections. 
Taking into account that GzmA deficiency does not 
affect pathogen control (our own results and [5]), our 
combined results in human and mouse models 
suggest that extracellular GzmA is a promising target 
to treat peritoneal sepsis.  
Materials and Methods 
Mouse Strains 
Inbred C57BL/6 (WT) and granzyme A deficient 
mouse strains (GZMA-/-) were maintained at the 
Biomedical Research Centre of Aragon (CIBA). 
GZMA-/- mice are bred in our animal house 
employing mice originally provided by Markus 
Simon´s laboratory. Their genotypes were 
periodically analysed as described [53]. Mice of 8–12 
weeks of age were used in all the experiments. Animal 
experimentation was approved by the Animal 
Experimentation Ethics Committee of the University 
of Zaragoza (number: PI43/13). 
Patients and study design 
A total of 10 patients with a diagnose of 
peritonitis and with a SOFA ((Sepsis related Organ 
Failure Assessment) score ≥2 were prospectively 
recruited over a 3-month period in 2019 after 
admission to Lozano Blesa Hospital in Zaragoza, 
Spain. Blood samples were collected at diagnosis 
(time 0) and during the first 72 hours. Blood samples 
were spun down at 2000 xg for 10 min and serum was 
collected and stored at -80 °C. GzmA concentration in 
serum was determined by ELISA.  
Cecal Ligation and Puncture 
Polymicrobial sepsis (PMS) was induced by CLP 
performed according to general guidelines [54]. WT 
and GZMA-/- mice were anesthetized using 2% 
isoflurane in oxygen. After disinfecting the abdomen, 
a 1 cm midline incision was performed to expose the 
cecum. From the tip, 1 cm of the cecum was ligated 
using a non-absorbable suture 3-0 (Silkam black 3/0 
HS26, Braun) and subsequently perforated twice by a 
through-and-through puncture with a 20G needle. 
After gently squeezing the cecum, to extrude 
sufficient amount of faeces from the perforation, the 
cecum was returned to the peritoneal cavity and the 
abdominal musculature was sutured with absorbable 
suture 3-0 (Novosyn violet 3/0 HR26, Braun). The 
skin was then sutured with non-absorbable suture 3.0 
and a subcutaneous dose of 0.05 mg/kg of 
buprenorphine in 1 mL of normal saline was 
administered. After 6 h of the intervention a mixture 
of antibiotics, ceftriaxone (30 mg/kg) + Metronidazole 
(12.5 mg/kg), was administered i.p. (intraperitoneal) 
once a day for 5 days. WT and GZMA-/- sham 
operated mice underwent the same procedure but 
without CLP.  
Mouse survival was monitored for 14 days. Mice 
were observed three times a day and if there were 
signs of respiratory distress, pain when touching, 
vocalisations, hunched posture or inability of a supine 
animal to stand, the human endpoint was applied. 
E. coli sepsis induction  
The most frequent Gram-negative bacteria, an E. 
coli strain, was isolated from blood of WT mice after 
24 h of sepsis induced by CLP. Bacteria was stored at 
-80 °C in Luria-Bertani medium (LB; sigma) with 10% 
glycerol. The inoculum for sepsis induction was 
prepared from 10 μL of E. coli cultured in LB medium 
at 37 °C to exponential growth phase and washed 
twice with phosphate-buffered saline (PBS). 
Absorbance at 600 nm was measured in a 
spectrophotometer to estimate the number of bacteria 
in the culture. The density of bacteria was adjusted to 
1x109 bacteria/mL. Sepsis was induced in WT, 
GZMA-/-, and GZMA (+/+, -/-) littermate mice by i.p. of 
2x108 bacteria in 200 μL of PBS.  
Mouse survival was monitored for 5 days. Mice 
were observed three times a day and if there were 





signs of respiratory distress, pain when touching, 
vocalisations, hunched posture or inability of a supine 
animal to stand, the human endpoint was applied.  
Collection of blood, peritoneal lavage fluid and 
organs  
After 6 and 24 h of sepsis induction, a group of 
septic WT and GZMA-/- mice as well as sham 
operated mice were sacrificed and blood samples 
were obtained aseptically by cardiac puncture. 
Anticoagulated blood was kept on ice until further 
processing for bacteriologic analysis. The rest of blood 
samples were centrifuged at 2000 xg for 15 min, and 
plasma was recovered and stored at -80 ºC. To collect 
peritoneal lavage fluid, 5 mL of sterile PBS was slowly 
injected into the peritoneal cavity with a 18G needle. 
The abdomen was gently massaged and then the 
peritoneal fluid was recovered. Part of it was used for 
bacteriological analysis while the rest was centrifuged 
at 2000 xg for 10 min and the supernatant was stored 
at -80 ºC. Finally, spleen, liver and lungs were 
collected aseptically, homogenized in 1 mL of PBS and 
used for bacteriological analysis. 
Aerobic bacterial count and characterization 
by MALDI-TOF mass spectrometry 
Peritoneal lavage fluid, blood and homogenized 
organs were serially diluted in PBS and plated by 
duplicate onto MacConkey and Columbia CNA agar 
(Biomériux), which were incubated aerobically for 48 
h at 37 °C. Plates that contained between 30 and 300 
colonies were counted and the number of CFU was 
determined. Aerobic bacterial isolates were identified 
by MALDI-TOF mass spectrometry. 
Infection of bone marrow macrophages with E. 
coli  
M2 macrophages were differentiated from 
mouse bone marrow (BM). Cells were aseptically 
collected form BM and resuspended in RPMI medium 
supplemented with 10% of FCS serum, 100 U/mL of 
penicillin/streptomycin, 50 mM of 2-ME, and 10% 
supernatant of L-929 cell culture as source of M-CSF. 
Cells were seeded at a density of 1 x 106 cells/mL and 
allowed to differentiate for 6 days at 37 °C and 5% 
CO2 atmosphere. For in vitro E. coli infection 
experiments, 5 x 105 macrophages were seeded in 96 
well plates, incubated with 300 nM of active GzmA 
and infected with E. coli at a MOI of 1:100 for 1 h at 37 
°C and 5% CO2. Subsequently, medium was removed, 
cells were washed with PBS and further incubated 
with complete RPMI medium containing 30 μg/mL of 
gentamycin for 1 h. Cells were washed and incubated 
with complete RPMI medium for 4, 24 and 48 h. After 
incubation periods, the macrophages were lysed with 
Triton-X 0.1% and CFU number was determined. 
Inflammation induced by GzmA in bone 
marrow derived macrophages 
M1 Macrophages were differentiated from WT 
and TLR4-/- mouse bone marrow. Cells were 
aseptically collected from femurs and tibias and 1 x106 
cells were cultured on 100 mm petri dishes with 10 
mL of RPMI 1640 medium containing 10% of FCS 
serum, 100 U/mL of penicillin/streptomycin, 50 mM 
of 2-ME, and 10% of supernatant of X63Ag8653 cell 
cultures as source of GM-CSF [55] (complete 
medium). On days 3 and 5, the supernatant was 
removed and 10 mL of fresh complete medium was 
added. On day 7, macrophages showed a complete 
differentiated phenotype expressing CD11b and 
F4/80. WT and TLR4-/- macrophages were stimulated 
with active GzmA (300 nM), GzmA inactivated with 
the inhibitor serpinb6b (2,4 µM), E. coli-derived LPS 
(100 ng/mL) or heat killed S. aureus (S. aureus HK,1 
x108 CFU/mL). In some experiments, LPS, GzmA, 
serpinb6b and cathepsin C (Sigma) were added at 
different concentrations. After 24 h of incubation, the 
supernatant was collected to determine the cytokine 
levels by ELISA. 
Inflammation induced by human GzmA in 
monocytes 
Monocytes were isolated from peripheral blood 
of healthy donors by a ficoll gradient centrifugation. 
Diluted blood was carefully layered on top of 15 mL 
of Histopaque ®-1077 (1.077 g/mL) (Sigma) solution. 
Centrifugation was performed for 10 min at 1455 xg 
without brake. After centrifugation, the white ring of 
peripheral blood monuclear cells (PBMCs) were 
collected, resuspended in 15 mL of complete DMEM 
medium (10% of FCS serum, 100 U/mL of 
penicillin/streptomycin, 50 mM of 2-ME), placed on a 
75 cm2 flask and incubated for 2 h at 37 °C and 5% CO2 
to allow monocytes to adhere at the flask bottom. 
After 2 h of incubation, cells were washed with PBS to 
remove cells in suspension. Adherent cells were 
trypsinized and 5 x 105 monocytes were seeded in 96 
well plates and incubated for 2 h to allow them to 
adhere. Monocytes were stimulated with LPS (100 
ng/mL), human GzmA (300 nM), antithrombin III (8.6 
μM), and heparin (430 μM). After 24 h of incubation, 
supernatant was collected to determine IL-6 by 
ELISA.  
Recombinant GzmA expression from Pichia 
pastoris 
P. pastoris expressing mouse proGzmA was 
grown at 30 °C for 36 h, and then allowed to settle for 
12 h at room temperature; growth medium was 





replaced with induction medium containing 3% 
methanol and 0.5 M arginine. Induction was 
performed at 23 °C for 60 h. Culture was 
centrifugated, the supernatant was collected and then 
filtered. Recombinant proGzmA was purified by 
cation exchange chromatography. Active GzmA was 
obtained using cathepsin C which hydrolyse the 
N-terminal dipeptide present in proGzmA. After 
activation, cathepsin C was not removed and active 
GzmA was stored at -80 °C until further use.  
Recombinant GzmA expression from 
Escherichia coli 
Mouse proGzmA was cloned into pET21a and 
transformed into E. coli BL21. For protein production, 
E. coli expressing proGzmA were grown at 37 °C until 
the culture reached an optical density at 600 nm 
between 0.6 and 0.8. The protein expression was 
induced adding IPTG 1 mM and incubating for 3 
hours at 37 °C. The culture was centrifugated at 8300 
xg for 15 min. The supernatant was discarded and the 
pellet was resuspended in lysis buffer (Tris-HCl 20 
mM, NaCl 100 mM, DTT 2 mM, lysozyme 2 mg/mL, 
DNAse 1 mg/mL and protein inhibitor). Bacteria was 
lysed by sonication, centrifugated at 48400 xg for 15 
min at 4 °C and the supernatant was discarded. 
Previously obtained inclusion bodies were 
resuspended in buffer denaturation (100 mM 
Tris-HCl, 6 M GuCl2, 20 mM EDTA and 10 mM 
oxidized DTT) and then centrifugated at 48400 xg for 
15 min at 4 °C. Proteins were refolded in 100 volumes 
of refolding buffer (100 mM Tris-HCl, 500 mM 
arginine, 10% glycerol and 10 mM oxidized DTT) for 3 
days at 4 °C and then dialyzed five times in MT-PBS. 
Recombinant proGzmA was purified by cation 
exchange chromatography. Active GzmA was 
obtained using cathepsin C which hydrolyse the 
N-terminal dipeptide present in proGzmA. After 
activation, active GzmA was stored at -80 °C until 
further use. Cathepsin C was inactivated by 
increasing pH to 7.4 and it was confirmed that it did 
not induce the generation of inflammatory cytokines 
in macrophages. 
Recombinant mouse serpinb6b expression 
from Pichia pastoris 
Pichia pastoris expressing serpinb6b was kindly 
provided by Phil Bird from Monash University, 
Australia. P. pastoris expressing serpinb6b was grown 
at 30 °C for 36 h and then allowed to settle for 12 h at 
room temperature; growth medium was replaced 
with induction medium containing 3% methanol and 
0.5 M Arginine. Induction was performed at 23 °C for 
60 h. Culture was centrifuged and a chemical and 
physical lysis was performed. After supernatant 
clarification, recombinant serpinb6b was purified by 
immobilized metal (Nickel) affinity chromatography. 
LPS quantification in mouse and human GzmA 
preparations 
Mouse and human proGzmA LPS quantification 
was carried out using the Toxin Sensor™ Endotoxin 
Detection System (GenScript). Samples were treated 
and analyzed following the manufacturer 
instructions. The amount of LPS in all protein 
preparations was always lower than 0.5 EU/μg 
protein.  
Determination of GzmA and cytokine levels 
Levels of mouse IL-1α, IL-1β, TNFα and IL-6 
were measured in peritoneal fluid and plasma, 6 and 
24 h after CLP induction using commercial ELISA kits 
(Invitrogen). Human serum GzmA levels from 
healthy donors and patients with confirmed 
abdominal sepsis at diagnosis and during the first 72 
h was monitored by a commercial ELISA kit (Human 
Granzyme A DuoSet ELISA, R&D Systems) following 
the manufacturer recommendations. 
Isolation of Mouse Peripheral Blood 
Lymphocytes (PBLs) 
After 24 h of sepsis induction, WT and GZMA-/- 
mice were sacrificed. Total blood was collected 
aseptically by cardiac puncture in presence of 
anticoagulants Sodium Citrate 3.8%. PBLs were 
isolated by gradient centrifugation. 1 mL of total 
blood was mixed with 1 mL PBS. To a conical 15 mL 
tube, 2 mL of Histopaque-1077® was added and then 
blood was carefully layered on top. Next, the sample 
was centrifuged at 400 xg for 30 min at room 
temperature. Mononuclear cells were collected from 
the opaque interface. 
Intracellular expression of GzmA 
After 24 h of sepsis induction, WT and GZMA-/- 
mice were sacrificed. Blood and spleen were collected 
aseptically. PBLs were isolated from blood as 
described above and spleen was homogenized in 5 
mL of RPMI medium. 2x105 PBLs or splenocytes were 
stained with anti CD3-FITC, anti CD8-APC, anti 
NK1.1-APC-Vio770 and anti CD4-VioBlue from 
Miltenyi Biotec. Subsequently, cells were fixed with 
paraformaldehyde (PFA) 1%, permeabilised with 
saponin 1% in PBS and incubated with anti gzmA-PE 
(eBioscience) or with the corresponding isotype 
control (IgG2b kappa isotype control PE, 
eBiosciencie). Finally, intracellular expression of 
GZMA was analysed by FACS. 





Therapeutic inhibition of extracellular GzmA 
with Serpinb6b 
After sepsis induction a group of WT and 
GZMA-/- mice were treated with 40 µg of the GzmA 
inhibitor serpinb6b i.p. The inhibitor was 
administrated after 6 h and once a day for 5 days 
combined with ceftriaxone (30 mg/kg) + 
metronidazole (12.5 mg/kg). Survival was monitored 
for 14 days.  
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